We could not find any results for:
Make sure your spelling is correct or try broadening your search.
http://www.fool.com.au/2015/05/29/alchemia-limited-slammed-53-is-the-stock-a-buy/
Alchemia Limited (ASX:ACL), today announced the initiation of recruitment for a Phase II clinical study of its lead cancer drug HA-Irinotecan in Small Cell Lung Cancer (SCLC...
Dr. Reddy's Laboratories Ltd. (500124.BY) said Wednesday it has received U.S. regulatory approval to launch a copy of GlaxoSmithKline PLC's (GSK) anticlotting Arixtra injection, which is expected...
Dr. Reddy’s Laboratories (NYSE: RDY) and Alchemia Limited, Brisbane, Australia (ASX: ACL) announced today that Dr. Reddy’s has received final approval of Dr. Reddy’s ANDA for...
Dr. Reddy's Laboratories Ltd. (500124.BY) said Wednesday it has received final approval from the U.S. Food and Drug Administration to sell a generic version of GlaxoSmithKline PLC's (GSK) Arixtra...
Alchemia Limited (ASX: ACL) announced today that Pete Smith, Chief Executive Officer, is scheduled to present a corporate update at the Cowen and Company 31st Annual Health Care...
Alchemia (ASX:ACL) today announced the agreement of terms with Dr Reddy’s Limited for marketing fondaparinux sodium for injection (the generic version of GlaxoSmithKline’s...
Alchemia’s (ASX: ACL) subsidiary Alchemia Oncology today presented two posters at the American Association of Cancer Research (AACR) 101st Annual Meeting in Washington, DC. The...
Emisphere Technologies, Inc. (OTCBB:EMIS) and Alchemia Ltd. (ASX:ACL) today announced that they are joining efforts to develop an oral formulation of the anti-coagulant drug...
("Alcon 3Q Profit Down 18%, Raises 2009 Earnings View 2nd Time," published at 6:12 p.m. EDT, incorrectly included a tax benefit for the latest quarter. The correct version follows.) DOW JONES...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.05 | -1.31578947368 | 3.8 | 3.82 | 3.62 | 997370 | 3.70150245 | DE |
4 | 0.55 | 17.1875 | 3.2 | 3.84 | 3.16 | 1526140 | 3.5757325 | DE |
12 | 1.38 | 58.2278481013 | 2.37 | 3.84 | 2.25 | 1412012 | 3.00178835 | DE |
26 | 1.21 | 47.6377952756 | 2.54 | 3.84 | 2.14 | 989023 | 2.79930705 | DE |
52 | 0.9 | 31.5789473684 | 2.85 | 3.84 | 2.14 | 721315 | 2.77718356 | DE |
156 | -0.53 | -12.3831775701 | 4.28 | 6.39 | 2.14 | 705972 | 3.6194198 | DE |
260 | 3.739 | 33990.9090909 | 0.011 | 6.39 | 0.011 | 705021 | 3.65903269 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions